ArticleNature2021
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Open access · hybridAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 287 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
287citing papers in PubMed, 7 pooled it
41.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
287 citing papers in PubMed, 7 syntheses or guidelines pooled it, 411 citations in OpenAlex.
- Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.BMC cancer · 2025Pooled it
- IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.Molecular oncology · 2024Pooled it
- Transformers meets neoantigen detection: a systematic literature review.Journal of integrative bioinformatics · 2024Pooled it
- Targeted agents in patients with progressive glioblastoma-A systematic meta-analysis of randomized clinical trials.Cancer medicine · 2024Pooled it
- Accuracy of Radiomics in PredictingRadiology. Artificial intelligence · 2024Pooled it
- The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations.Neuroradiology · 2023Pooled it
- Pertinence of glioma and single nucleotide polymorphism of TERT, CCDC26, CDKN2A/B and RTEL1 genes in glioma: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).Journal for immunotherapy of cancer · 2026Trial
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma.Nature communications · 2026Article
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Long-read sequencing reveals widespread novel splicing and neojunction-derived neoantigens in nasopharyngeal carcinoma.Genome research · 2026Article
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy.Journal of clinical medicine · 2026Review
- Nanotechnology-based immunotherapy: integrating Artificial Intelligence (AI) with current strategies in combating brain cancer disease.Journal of the Egyptian National Cancer Institute · 2026Review
- IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Nature cancer · 2026Article
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- Sequence-Anchored Shared Tumor-Specific Epitopes for Pre-Manufactured HLA-Matched mRNA Cancer Vaccine Libraries: A Pan-Cancer Framework.Biomolecules · 2026Article
- Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial.Nature communications · 2026Article
227 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
28 authors at 10 institutions in 1 country.
Michael PlattenDKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz.de.ORCID http://orcid.org/0000-0002-4746-887X
Lukas BunseDKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4490-7574
Antje WickNeurology Clinic, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
Theresa BunseDKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1834-4269
Lucian Le CornetNCT Trial Center, NCT, Heidelberg, Germany.
Inga HartingDepartment of Neuroradiology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
Felix SahmDKTK CCU Neuropathology, DKFZ, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5441-1962
Khwab SanghviDKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Chin Leng TanDKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Isabel PoschkeDKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Edward GreenDKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sune JustesenImmunitrack, Copenhagen, Denmark.
Geoffrey A BehrensDKMS Life Science Lab GmbH, Dresden, Germany.
Michael O BreckwoldtDepartment of Neuroradiology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-9980-2390
Angelika FreitagNCT Trial Center, NCT, Heidelberg, Germany.
Lisa-Marie RotherNCT Trial Center, NCT, Heidelberg, Germany.
Anita SchmittDepartment of Internal Medicine V, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
Oliver SchnellDepartment of Neurosurgery, University of Freiburg, Freiburg, Germany.
Jörg HenseDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0000-0003-4679-2026
Martin MischDepartment of Neurosurgery, Charité Medical Center, University of Berlin, Berlin, Germany.
Dietmar KrexDepartment of Neurosurgery, Carl Gustav Carus University Hospital, University of Dresden, Dresden, Germany.
Stefan StevanovicInstitute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Ghazaleh TabatabaiDepartment of Neurology, University of Tübingen, Tübingen, Germany.
Joachim P SteinbachDr. Senckenberg Institute of Neurooncology, Frankfurt, Germany.
Martin BendszusDepartment of Neuroradiology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
Andreas von DeimlingDKTK CCU Neuropathology, DKFZ, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5863-540X
Michael SchmittDepartment of Internal Medicine V, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
Wolfgang WickNeurology Clinic, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6171-634X
Heidelberg University · DEGerman Cancer Research Center · DENational Center for Tumor Diseases · DEUniversity of Tübingen · DECharité - Universitätsmedizin Berlin · DEDeutsche Knochenmarkspenderdatei · DESenckenberg Research Institute and Natural History Museum Frankfurt/M · DEUniversity Hospital Carl Gustav Carus · DEUniversity of Duisburg-Essen · DEUniversity of Freiburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma
Indexed as
MutationAdultCancer VaccinesCells, CulturedDisease ProgressionFemaleGliomaHumansIsocitrate DehydrogenaseMaleMutant ProteinsPhenotypeReceptors, Antigen, T-CellSurvival RateT-LymphocytesCancer VaccinesIDH1 protein, humanIsocitrate DehydrogenaseMutant ProteinsReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.